Author:
McCush Fred,Wang Ellen,Yunis Carla,Schwartz Pamela,Baltrukonis Daniel
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. FDA. Immunogenicity testing of therapeutic protein products —developing and validating assays for anti-drug antibody detection. Guidance for industry. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). 2019. Available from: https://www.fda.gov/media/119788/download.
2. Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of therapeutic proteins. 2017. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.
3. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658–73. https://doi.org/10.1208/s12248-014-9599-2.
4. Manning MS, Hassanein M, Partridge MA, Jawa V, Mora J, Ryman J, et al. Comparison of titer and signal to noise (S/N) for determination of anti-drug antibody magnitude using clinical data from an Industry Consortium. AAPS J. 2022;24:81. https://doi.org/10.1208/s12248-022-00728-8.
5. Manning MS, Kroenke MA, Lee SA, Harrison SE, Hoofring SA, Mytych DT, Jawa V. Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response. Bioanalysis. 2017;9(23):1849–58. https://doi.org/10.4155/bio-2017-0185.